OBJECTIVE: The apolipoprotein (apo)A-I mimetic peptide 5A is highly specific for ATP-binding cassette transporter (ABC)A1-mediated cholesterol efflux. We investigated whether the 5A peptide shares other beneficial features of apoA-I, such as protection against inflammation and oxidation. Methods- New Zealand white rabbits received an infusion of apoA-I, reconstituted high-density lipoprotein (HDL) containing apoA-I ([A-I]rHDL), or the 5A peptide complexed with phospholipids (1-palmitoyl-2-linoleoyl phosphatidylcholine [PLPC]), before inserting a collar around the carotid artery. Human coronary artery endothelial cells (HCAECs) were incubated with (A-I)rHDL or 5A/PLPC before stimulation with tumor necrosis factor alpha. Results- ApoA-I, (A-I)rHDL, and 5A/PLPC reduced the collar-mediated increase in (1) endothelial expression of cell adhesion molecules vascular cell adhesion molecule-1 and intercellular adhesion molecule-1; (2) production, as well as the expression of the Nox4 catalytic subunits of the NADPH oxidase; and (3) infiltration of circulating neutrophils into the carotid intima-media. In HCAECs, both 5A/PLPC and (A-I)rHDL inhibited tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression, as well as the nuclear factor kappaB signaling cascade and production. The effects of the 5A/PLPC complex were no longer apparent in HCAECs knocked down for ABCA1. CONCLUSIONS: Like apoA-I, the 5A peptide inhibits acute inflammation and oxidative stress in rabbit carotids and HCAECs. In vitro, the 5A peptide exerts these beneficial effects through interaction with ABCA1.
OBJECTIVE: The apolipoprotein (apo)A-I mimetic peptide 5A is highly specific for ATP-binding cassette transporter (ABC)A1-mediated cholesterol efflux. We investigated whether the 5A peptide shares other beneficial features of apoA-I, such as protection against inflammation and oxidation. Methods- New Zealand white rabbits received an infusion of apoA-I, reconstituted high-density lipoprotein (HDL) containing apoA-I ([A-I]rHDL), or the 5A peptide complexed with phospholipids (1-palmitoyl-2-linoleoyl phosphatidylcholine [PLPC]), before inserting a collar around the carotid artery. Human coronary artery endothelial cells (HCAECs) were incubated with (A-I)rHDL or 5A/PLPC before stimulation with tumor necrosis factor alpha. Results- ApoA-I, (A-I)rHDL, and 5A/PLPC reduced the collar-mediated increase in (1) endothelial expression of cell adhesion molecules vascular cell adhesion molecule-1 and intercellular adhesion molecule-1; (2) production, as well as the expression of the Nox4 catalytic subunits of the NADPH oxidase; and (3) infiltration of circulating neutrophils into the carotid intima-media. In HCAECs, both 5A/PLPC and (A-I)rHDL inhibited tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression, as well as the nuclear factor kappaB signaling cascade and production. The effects of the 5A/PLPC complex were no longer apparent in HCAECs knocked down for ABCA1. CONCLUSIONS: Like apoA-I, the 5A peptide inhibits acute inflammation and oxidative stress in rabbit carotids and HCAECs. In vitro, the 5A peptide exerts these beneficial effects through interaction with ABCA1.
Authors: T M Forte; M N Oda; L Knoff; B Frei; J Suh; J A Harmony; W D Stuart; E M Rubin; D S Ng Journal: J Lipid Res Date: 1999-07 Impact factor: 5.922
Authors: Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Susan Hama; Greg Hough; Joy S Frank; Victor R Grijalva; Vannakambadi K Ganesh; Vinod K Mishra; Mayakonda N Palgunachari; Alan M Fogelman Journal: Circ Res Date: 2005-08-11 Impact factor: 17.367
Authors: Jingsong Ou; Zhijun Ou; Deron W Jones; Sandra Holzhauer; Ossama A Hatoum; Allan W Ackerman; Dorothee W Weihrauch; David D Gutterman; Karen Guice; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard Journal: Circulation Date: 2003-05-05 Impact factor: 29.690
Authors: Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Susan Hama; Greg Hough; Victor R Grijalva; Alan C Wagner; Joy S Frank; Geeta Datta; David Garber; Alan M Fogelman Journal: Circulation Date: 2004-06-14 Impact factor: 29.690
Authors: Stephen J Nicholls; E Murat Tuzcu; Ilke Sipahi; Paul Schoenhagen; Tim Crowe; Samir Kapadia; Steven E Nissen Journal: J Am Coll Cardiol Date: 2006-02-09 Impact factor: 24.094
Authors: Steven E Nissen; Taro Tsunoda; E Murat Tuzcu; Paul Schoenhagen; Christopher J Cooper; Muhammad Yasin; Gregory M Eaton; Michael A Lauer; W Scott Sheldon; Cindy L Grines; Stephen Halpern; Tim Crowe; James C Blankenship; Richard Kerensky Journal: JAMA Date: 2003-11-05 Impact factor: 56.272
Authors: Wilissa D'Souza; John A Stonik; Andrew Murphy; Steven J Demosky; Amar A Sethi; Xiao L Moore; Jaye Chin-Dusting; Alan T Remaley; Dmitri Sviridov Journal: Circ Res Date: 2010-05-27 Impact factor: 17.367
Authors: Scott M Gordon; Mohsen Pourmousa; Maureen Sampson; Denis Sviridov; Rafique Islam; B Scott Perrin; Georgina Kemeh; Richard W Pastor; Alan T Remaley Journal: Biochim Biophys Acta Biomembr Date: 2016-11-01 Impact factor: 3.747
Authors: Una L Kelly; Daniel Grigsby; Martha A Cady; Michael Landowski; Nikolai P Skiba; Jian Liu; Alan T Remaley; Mikael Klingeborn; Catherine Bowes Rickman Journal: J Biol Chem Date: 2020-07-31 Impact factor: 5.157
Authors: A Tran-Dinh; D Diallo; S Delbosc; L Maria Varela-Perez; Q B Dang; B Lapergue; E Burillo; J B Michel; A Levoye; J L Martin-Ventura; O Meilhac Journal: Br J Pharmacol Date: 2013-06 Impact factor: 8.739